The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
And much more to come next week, post Saturday’s poster presentation.
Novartis attending presentation.
The company have said recently Precision Oncology is where they want to be.
Novartis, Lilly and Roche and Takeda big fans of Fiona.
More to come!
Monday opening price, comfortably in the sixties.
With P1b no longer required and when the 2 weekly study shows the expected result, one would expect Dr. Tap and Avacta using the 2 weekly study for P2.
Useful to have est. cost savings which should be significant.
The Poster presentation Saturday should attract an awful lot of interest , with of course Novartis attending.
Watch the size buyers this afternoon writing tickets and pushing the price easily back above 160!
Yes that is how these conferences works, it does put someone like Fiona on the spot for Q&A with Audience.
An RNS in the morning U.K. time, would certainly lift the profile of the company even faster.
Hopefully you all took advantage of the share price two weeks ago.
One could off course also argue, that we have a stock moving higher supported by above average volume and market anticipating the upcoming presentation at AACR conference highlighting AVA3996, AVA6000 and indeed the entire AVA Platform and it‘s potential value going forward.When asked before, industry observers have suggested one applies a 1 billion dollars to each AVA as an average.
The market is growing at pace and we have barely begun.
Good luck to everybody who have taken profit, just don’t forget to jump back on again, we are leaving very soon!
With Biotech sector up and running with M&A on almost daily basis, having Avacta presenting at AACR twice and as we know now, it is the whole AVA platform, which Avacta will also discuss and the market will quickly understand the potential magnitude of the whole precision oncology market, as will the majors !
With the Conference starting Wednesday the 11th, one would assume that Tuesday the 10th will be pre conference day, with all the majors arriving and the same for the speakers and indeed Avacta with their first presentation due at midday Thursday, hence a license deal could very likely be announced tomorrow.
Post market prints could show size and price above current level.
In view of what will be a very upbeat presentation y Avacta in Boston, “ AVA6000 at pace “ and AVA3996 + AVA032 “ The data to be presented showcases the potential of our two therapeutic platforms to generate further high value clinical assets.”
One would expect further keen size buyers this afternoon, trusting a License deal to be announced next week prior to the presentation in Boston and ESMO in Madrid the following week.